The Drug Safety Strategies to De-Risk Compounds conference, which is part of IBC USA's Drug Discovery & Development Week, has been developed to provide participiants with the latest data from preclinical models to predict hepatotoxicity, cardiotoxicity and muscle toxicity that are having an impact today on decisions about whether to progress a compound or withdraw it from development. Specific examples of projects translating preclinical safety predictions to the clinic will be presented to illustrate these models.

Lauren Black, senior scientific advisor at Charles River, and Alain Stricker-Krongrad, chief scientific officer from Charles River, will be participating in a point/counterpoint session titled "Are Animal Models of Disease Predictive of Human Drug Safety?"

This session, held on August 5 at 5:20pm, will debate the merits of current animal models of cardiovascular toxicity and hepatotoxicity. Panelists will address both sides of the question including the following issues:

• What are the current models and how are they performed? (eg. species/normal or genetically modified etc.)
• What are the plusses and limitations of current models? Which are predictive and which are not?
• Can one translate results (positive or negative) into people?
• Do animal models provide too much information?
• What are the regulatory requirements and considerations when using animal safety models?
• What is the impact of the European guidance on use of animals for predicting dose in humans.

Attendees will receive a 25% discount by using priority code D9201SKRD when registering.

For details about the Drug Safety Strategies to De-Risk Compounds conference, click here or contact us at events@crl.com.